Literature DB >> 28374332

Prevalence and risk factors associated with glucocorticoid-induced osteoporosis in Chinese patients with rheumatoid arthritis.

Can-Chen Ma1, Sheng-Qian Xu2, Xun Gong1, Ying Wu1, Shan Qi1, Wen Liu1, Jian-Hua Xu1.   

Abstract

Usage of glucocorticoid (GC) is a strong risk factor of osteoporosis (OP) and osteoporotic fracture (OPF) in Chinese patients with rheumatoid arthritis (RA). Controlling GC daily dosage and shortening GC course are helpful in preventing glucocorticoid-induced osteoporosis (GIOP) and OPF for Chinese patients with RA.
INTRODUCTION: This study aims to investigate the prevalence and risk factors of GIOP, and also identify influences of GC daily dosage and GC treatment course for GIOP in Chinese patients with RA.
METHODS: Seven hundred and ninety patients with RA and 158 normal subjects were enrolled in the study. Clinical and laboratory features and medications of GC were recorded in detail. Bone mineral density (BMD) was measured by dual energy X-ray absorptiometry in all subjects.
RESULTS: BMD at all measured sites in RA was significantly lower than that in control group. Prevalence of OP was obviously higher in RA with GC group (41.6%), compared with RA without GC group (29.4%). Prevalence of OPF in group of RA with GC (21.0%) was higher than that in group of RA without GC (13.3%). Usage of GC, female, and age were risk factors for the occurrence of OP and OPF in RA, while body mass index (BMI) was the protective factor of OP. Prevalence of GIOP and OPF had statistical significance among groups of different treatment courses with GC, whereas no statistical difference was found among groups with different daily dosages of GC.
CONCLUSIONS: GIOP exists generally in Chinese patients with RA, which relates to treatment course not daily dosage of GC. Usage of GC is also the risk factor for the happening of OPF in Chinese patients with RA.

Entities:  

Keywords:  Glucocorticoid-induced osteoporosis; Osteoporotic fracture; Rheumatoid arthritis

Mesh:

Substances:

Year:  2017        PMID: 28374332     DOI: 10.1007/s11657-017-0329-0

Source DB:  PubMed          Journal:  Arch Osteoporos            Impact factor:   2.617


  4 in total

1.  The Impact of Seropositivity on Systemic Bone Loss in Rheumatoid Arthritis-A 3-Year Interim Analysis of a Longitudinal Observational Cohort Study.

Authors:  Shan-Fu Yu; Jia-Feng Chen; Ying-Chou Chen; Yu-Wei Wang; Chung-Yuan Hsu; Han-Ming Lai; Hsiao-Ru He; Chi-Hua Ko; Wen-Chan Chiu; Tien-Tsai Cheng
Journal:  Front Med (Lausanne)       Date:  2022-06-09

2.  Lean Mass and Disease Activity are the Best Predictors of Bone Mineral Loss in the Premenopausal Women with Rheumatoid Arthritis.

Authors:  Meha Sharma; Urmila Dhakad; Anupam Wakhlu; Danveer Bhadu; Deep Dutta; Siddharth K Das
Journal:  Indian J Endocrinol Metab       Date:  2018 Mar-Apr

3.  Establishment of a preliminary FRAX®-based intervention threshold for rheumatoid arthritis-associated fragility fracture: a 3-year longitudinal, observational, cohort study.

Authors:  Shan-Fu Yu; Ming-Han Chen; Jia-Feng Chen; Yu-Wei Wang; Ying-Chou Chen; Chung-Yuan Hsu; Han-Ming Lai; Wen-Chan Chiu; Chi-Hua Ko; Hsiao-Ru He; Tien-Tsai Cheng
Journal:  Ther Adv Chronic Dis       Date:  2022-02-25       Impact factor: 5.091

4.  Prevalence of osteoporosis among the elderly population of Iran.

Authors:  Noushin Fahimfar; Sima Noorali; Shakiba Yousefi; Safoora Gharibzadeh; Gita Shafiee; Nekoo Panahi; Mahnaz Sanjari; Ramin Heshmat; Farshad Sharifi; Neda Mehrdad; Alireza Raeisi; Iraj Nabipour; Bagher Larijani; Afshin Ostovar
Journal:  Arch Osteoporos       Date:  2021-01-21       Impact factor: 2.617

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.